Class Action Article

  • File A Talcum Powder Lawsuit: Talcum Powder Ovarian Cancer Lawsuits Talcum Powder Fallopian Tube Cancer Lawsuits Baby  Powder Ovarian Cancer Lawsuits Filed If you or a loved one used talcum powder products and were diagnosed with ovarian cancer, or fallopian tube can...

Class Action News

Drug Class Actions

  • Taxotere Lawyers for Permanent Hair Loss: Taxotere Baldness Lawyers For  Permanent Hair Loss Lawsuits Have you received Taxotere for breast cancer? Taxotere can result in hair loss or baldness  that is permanent. Taxotere  is a chemotherapy drug used for the treatment of breas...

Medical Device Lawsuits

  • Get A Hernia Mesh Lawyer | Hernia Mesh Lawsuits Filed: The hernia mesh lawyers of Class Action Lawyer Network are filing hernia mesh lawsuits for victims of a failed hernia mesh. We have Ethicon, Bard and Cook hernia mesh lawyers. Hernia Mesh Lawsuits Filed  For: Ethicon: Physiomesh Pro...

Posts Tagged ‘File an actos lawsuit’

I Have Heard Actos Can Cause Bladder Cancer? Is That True? How Do I File An Actos Lawsuit

Written by lisaspitzer on . Posted in Actos Lawsuit Lawyers, Drug Warnings

Actos does have warnings for bladder cancer with use for extended periods of time. Actos lawyers are filing lawsuits for people who have developed bladder cancer as a part of a multi district litigation.

FDA Warnings For Actos and Bladder Cancer

FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer

Actos Bladder Cancer Safety Announcement

[6-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines.

Actos Bladder Cancer Lawsuit

Actos lawsuits are being  filed on behalf of type II diabetics who developed bladder cancer from long-term use of the  drug Actos. These lawsuits continue to move forward in a multidistrict litigation in U.S. District Court, Western District of Louisiana. More than 2,500 Actos bladder cancer lawsuits are currently pending in the Western District of Louisiana, where the first trials are scheduled to begin in January.

Actos Product Liability Litigation, MDL No. 2299

If you believe you, a loved one or someone you are a caregiver for has gotten bladder cancer and has been on Actos call and speak to an Actos lawyer today. There must be a confirmed diagnosis of bladder cancer to be added to the lawsuit.

FDA Quick Review Process, Dangerous Drugs And Devices Pushed Thru On The Fast Track

Written by lisaspitzer on . Posted in Class MDL Class Action News

Class Action lawyers Filing lawsuits for vaginal mesh, Bladder sling, Stryker Hip replacements and other Hip replacements, GranuFlo, Actos, Pradaxa, Mirena IUD, and many others. Many devices harming victims were pushed thru on the FDA fast track process.

Medical Devices and the Public’s Health: The FDA 510(k) Clearance Process at 35 Years

Released:
    July 29, 2011
Type:
    Consensus Report
Topics:
    Public Health, Quality and Patient Safety
Activity:
    Public Health Effectiveness of the FDA 510(k) Clearance Process
Board:
    Board on Population Health and Public Health Practice

Medical devices play a critical role in the health care of Americans. They can range from simple tools, such as tongue depressors and bandages, to complex or life-saving equipment, such as pacemakers, magnetic resonance imaging machines, and heart–lung machines. The Federal Food, Drug, and Cosmetic Act (FFDCA) requires a "reasonable assurance of safety and effectiveness" before a device can be marketed, and the U.S. Food and Drug Administration (FDA) is responsible for enforcing this requirement. Devices that are deemed to have a moderate risk to patients generally cannot go on the market until they are cleared through the 510(k) process, named for Section 510(k) of the FFDCA.  Some policymakers and patients have expressed concern about the ability of the 510(k) process to ensure that medical devices on the market are safe and effective. Other policymakers and patients, as well as the medical-device industry, have asserted that the process has become too burdensome and time-consuming and that it is delaying important new medical devices from entering the market.

The FDA turned to the IOM to review the 510(k) process and answer two questions:

    Does the current 510(k) process protect patients optimally and promote innovation in support of public health?
    If not, what legislative, regulatory, or administrative changes are recommended to achieve the goals of the 510(k) process optimally

The IOM finds that the current 510(k) process is flawed based on its legislative foundation. Rather than continuing to modify the 35-year-old 510(k) process, the IOM concludes that the FDA’s finite resources would be better invested in developing an integrated premarket and postmarket regulatory framework that provides a reasonable assurance of safety and effectiveness throughout the device life cycle. The IOM outlines its criteria for this framework in the report.